TRPV1: A Potential Therapeutic Target in Type 2 Diabetes and Comorbidities?

被引：41

作者：

Gram, Dorte X. ^{[1
]}

Holst, Jens J. ^{[2
]}

Szallasi, Arpad ^{[3
]}

机构：

[1] Pila Pharma, Malmo, Sweden

[2] Univ Copenhagen, Panum Inst, Copenhagen, Denmark

[3] Baptist Med Ctr, Jacksonville, FL USA

来源：

TRENDS IN MOLECULAR MEDICINE | 2017年 / 23卷 / 11期

关键词：

GENE-RELATED PEPTIDE; SENSORY NERVE DESENSITIZATION; SUBSTANCE-P; INSULIN-SECRETION; GLUCOSE-TOLERANCE; PERIPHERAL NEUROPATHY; INFLAMMATORY MARKERS; VANILLOID RECEPTOR-1; CAPSAICIN RECEPTORS; ISLET INFLAMMATION;

D O I：

10.1016/j.molmed.2017.09.005

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

With an estimated 422 million affected patients worldwide in 2016, type 2 diabetes (T2D) has reached pandemic proportions and represents a major unmet medical need. T2D is a polygenic disease with a chronic, low-grade inflammatory component. Second-generation transient receptor potential vanilloid-1 (TRPV1) antagonists are potent anti-inflammatory agents with proven clinical safety. In rodent models of T2D, TRPV1 blockade was shown to halt disease progression and improve glucose metabolism. Thus, we propose that TRPV1 antagonists merit further study as novel therapeutic approaches to potentially treat T2D and its comorbidities.

引用

页码：1002 / 1013

页数：12

共 50 条

[1] TRPV1: A Potential Therapeutic Target for Myocardial Infarction?
Cao, Lu
Cheng, Lihua
Xu, Jing
CARDIOLOGY, 2017, 136 (03) : 156 - 156
[2] TRPV1: A Potential Drug Target for Treating Various Diseases
Brito, Rafael
Sheth, Sandeep
Mukherjea, Debashree
Rybak, Leonard P.
Ramkumar, Vickram
CELLS, 2014, 3 (02) : 517 - 545
[3] TRPV1: A novel target for the therapy of diabetes and diabetic complications
Shen, Yu-rong
Cheng, Long
Zhang, Dong-fang
EUROPEAN JOURNAL OF PHARMACOLOGY, 2024, 984
[4] Potential therapeutic value of TRPV1 and TRPA1 in diabetes mellitus and obesity
Derbenev, Andrei V.
Zsombok, Andrea
SEMINARS IN IMMUNOPATHOLOGY, 2016, 38 (03) : 397 - 406
[5] TRPV1: A useful therapeutic target for patients with vulnerable coronary plaques
Li, Yan Bo
Huang, Cong Xin
MEDICAL HYPOTHESES, 2011, 77 (03) : 453 - 455
[6] THE TRPV1 CHANNEL AS A TARGET FOR THE TREATMENT OF PAIN
Salazar, H.
Jara-Oseguera, A.
Rosenbaum, T.
REVISTA DE NEUROLOGIA, 2009, 48 (07) : 357 - 364
[7] The Vanilloid (Capsaicin) Receptor TRPV1 in Blood Pressure Regulation: A Novel Therapeutic Target in Hypertension?
Szallasi, Arpad
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (10)
[8] Glucagon antagonism as a potential therapeutic target in type 2 diabetes
Bagger, J. I.
Knop, F. K.
Holst, J. J.
Vilsboll, T.
DIABETES OBESITY & METABOLISM, 2011, 13 (11) : 965 - 971
[9] TRPV1 and TRPV4 channels: Potential therapeutic targets for ischemic conditioning-induced cardioprotection
Randhawa, Puneet Kaur
Jaggi, Amteshwar Singh
EUROPEAN JOURNAL OF PHARMACOLOGY, 2015, 746 : 180 - 185
[10] The potential role of TRPV1 in pulmonary hypertension: Angel or demon?
Zhang, Xin
Ye, Lifang
Huang, Yu
Ding, Xueyan
Wang, Lihong
CHANNELS, 2019, 13 (01) : 235 - 246

← 1 2 3 4 5 →